The interplay between proteasome inhibition and cellular stress response pathways is a critical determinant of therapeutic efficacy in urothelial carcinoma. Bortezomib, a reversible proteasome inhibitor, induces endoplasmic reticulum (ER) stress and protein aggregation, leading to apoptosis in cancer cells. However, the activation of cytoprotective mechanisms, particularly the heat shock response, often limits its antitumor effects. This study focuses on the role of inducible Hsp72 in modulating bortezomib sensitivity across human bladder cancer cell lines, revealing a complex isoform-specific regulation that has significant implications for targeted therapy.
We evaluated four representative bladder cancer cell lines—253J B-V, SW780, UM-UC10, and UM-UC13—for their responses to bortezomib-induced cell death using propidium iodide staining and flow cytometry. The results showed marked heterogeneity: 253J B-V and SW780 cells were relatively resistant, while UM-UC10 and UM-UC13 exhibited high sensitivity. mRNA expression profiling revealed that resistance was associated with strong upregulation of HSPA1A, the major inducible isoform of Hsp72, following bortezomib exposure. In contrast, HSPA1A induction was minimal in the sensitive lines, despite intact HSF1 signaling and activation of other stress-responsive genes such as DNAJB1 and HSPB1.
Further investigation demonstrated that this differential induction was due to promoter methylation of HSPA1A in UM-UC10 and UM-UC13 cells. Bisulfite sequencing confirmed hypermethylation of CpG islands within the HSPA1A promoter region, which correlated with transcriptional silencing.Goat Anti-Chicken IgY H&L In Vitro Reversal of methylation using 5-aza-2′-deoxycytidine restored both basal and bortezomib-induced HSPA1A expression, confirming epigenetic regulation. Notably, these cells compensated by upregulating HSPA1B, resulting in comparable total Hsp72 protein levels across all four lines, as confirmed by immunoblotting.
Functional experiments underscored the protective role of Hsp72. Stable overexpression of HSPA1A in UM-UC10 and UM-UC13 cells significantly reduced bortezomib-induced cell death. Conversely, transient knockdown of HSPA1B using siRNA enhanced sensitivity in these cells. In 253J B-V cells, shRNA-mediated silencing of HSPA1A/B led to a dramatic increase in apoptosis, even at low bortezomib concentrations. Importantly, this sensitization was linked to lysosomal destabilization: Hsp72-depleted cells showed increased leakage of LysoTracker Red, indicating loss of lysosomal integrity—a key factor in autophagic flux and proteotoxicity.
In vivo validation was conducted using xenograft models. Nude mice implanted with 253J B-V cells transduced with Hsp72-targeting shRNA developed tumors that responded robustly to bortezomib treatment, showing near-complete growth suppression compared to control groups.Abraxane Microtubule/Tubulin Tumor RNA analysis confirmed sustained downregulation of HSPA1A in treated animals, supporting the relevance of the molecular mechanism observed in vitro.PMID:35196978
These findings highlight a novel vulnerability in bladder cancers with methylated HSPA1A promoters: dependence on HSPA1B for Hsp72 function. This creates an opportunity for synthetic lethality through selective inhibition of HSPA1B. Moreover, targeting upstream regulators like HSF1 with agents such as KNK-437 can effectively suppress Hsp72 induction and enhance bortezomib efficacy.
In conclusion, our data provide compelling evidence that Hsp72 is a dominant resistance factor in bladder cancer and that its inhibition—particularly via epigenetic or isoform-specific strategies—can potentiate the activity of proteasome inhibitors. These insights support the development of combination therapies involving bortezomib and Hsp72/HSF1 inhibitors, especially for tumors exhibiting HSPA1A silencing, offering a promising avenue for personalized treatment in urothelial malignancies.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com